Paraguay Condición de Venta: Sale Conditions under Article 25 and Labeling Duties

1. Key takeaways

1. Article 25 provides that the sale conditions (condición de venta) of a device are determined by DINAVISA at the time of registration, with four categories only:
   • a) Sale under prescription (Venta bajo receta)
   • b) Sale exclusively to health professionals and health institutions (Venta exclusiva a profesionales e instituciones sanitarias)
   • c) Free sale in pharmacies (Venta libre en farmacia)
   • d) Free sale (Venta Libre)
2. The sale condition is not a box the company freely chooses: it forms part of the registration decision and must be reflected on the labeling, so the approved condition governs both the certificate and every unit sold.
3. Changing the sale condition is a Class II change, which may only be implemented after authorization by DINAVISA, with an evaluation timeframe of 45 working days (Articles 13 and 14). The prohibition on implementing before approval applies immediately.
4. The operational instructions require that the sale condition field declared on the platform be proposed in accordance with Article 25, so the applicant’s proposal enters the file as a recommendation that DINAVISA confirms, adjusts or rejects in its decision.

2. Legal basis

Article 25 defines the closed list of four sale conditions; Articles 13 and 14 route any change of that condition through the Class II change procedure with its 45 working day evaluation; and Article 15 supplies the enforcement backdrop, since all changes may be subject to random inspection based on risk analysis and unreported changes may lead to suspension of the market authorization. The operational instructions add the practical layer at page 4, where the Condición de Venta field is declared on the platform. Together these provisions make the sale condition one of the most tightly coupled fields in the entire Paraguayan framework, linking registration, labeling and enforcement.

The four categories map cleanly onto distribution archetypes, which is why the field deserves commercial attention and not only regulatory attention. Sale under prescription presupposes a prescription chain and a dispensing partner; sale exclusively to health professionals and health institutions confines the product to institutional procurement and professional end users; free sale in pharmacies opens the retail channel while retaining the pharmacy as a supervised point of dispensing; and free sale removes the dispensing gate entirely. Because the applicant proposes the value on the platform and DINAVISA determines the condition at registration, the proposal should be supported by the intended use and the instructions for use already in the dossier; a proposal that contradicts the file is the easiest way to receive a narrower condition than the channel plan assumed.

3. Expert insights

Insight one: the sale condition directly determines the channel model. A device classified as sale exclusively to health professionals and health institutions cannot go through retail pharmacy channels; a device classified as sale under prescription requires a functioning prescription chain. This field is fixed at the time of registration, and if the channel the company envisions does not match the approved condition, the only route is a Class II change, which must be approved before any implementation. Channel strategy therefore has a regulatory prerequisite in Paraguay, and the cost of revising a channel model includes the change fee, the 45 working day evaluation and a label revision executed only after approval.

Insight two: the sale condition is a mandatory content item on the labeling. The labeling must display the approved sale condition, together with the wording AUTORIZADO POR DINAVISA and the registration or NSO number. Any labeling revision must verify that this item is updated in sync; otherwise the revision constitutes an unreported post-market change under Article 15. Because labeling artwork is often controlled by marketing teams rather than regulatory teams, this is precisely the field where synchronization fails in practice, and it deserves an explicit gate in the artwork approval workflow.

Insight three: the sale condition is a primary anchor during inspections. Article 15 provides that all changes may be subject to random inspection based on risk analysis, and unreported post-market changes discovered may lead to the suspension of the market authorization ex officio. Because the sale condition appears both on the certificate and on the label, it is the field most easily checked on site and most likely to reveal a discrepancy between what was approved and what is being sold. An inspector comparing a carton label against the certificate needs no technical expertise to identify a mismatch, which makes this the cheapest finding to prevent.

4. Practical recommendations

1. Define the target channel at project initiation and propose, at the time of application, a recommended sale condition matching that channel; the proposal should follow the definitions of Article 25 and be consistent with the intended use described in the dossier.
2. In label design, treat the approved sale condition as a fixed field that cannot be altered at will, managed in a separate zone from other label content so that marketing revisions cannot touch it without a regulatory check.
3. Before channel expansion, for example from the hospital segment into pharmacies, complete the Class II change and obtain approval first, and only then revise the label and distribute; the sequencing is approval, label, market.
4. Do not implement before the change is approved: Class II changes are subject to an immediate prohibition on implementation prior to authorization, and early implementation is itself an unreported change with suspension risk under Article 15.

5. Verification checklist

• □ Recommended sale condition matching the target channel proposed at application, consistent with the intended use
• □ Labeling displays the approved sale condition, the AUTORIZADO POR DINAVISA wording and the certificate number
• □ Channel expansion planned through a Class II change (45 working days) with the change filed before any distribution
• □ Labeling revisions checked for synchronization of the sale condition field through an artwork approval gate
• □ Confirmed that Class II changes require approval before implementation across the organization

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support for manufacturers, importers and authorized representatives in Paraguay, covering sale condition strategy, labeling compliance and change management under Resolución DINAVISA N° 226/2024. Contact: info@grzanglobal.com